Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing (INTASAH)

This study has been completed.
Sponsor:
Collaborators:
Abbott
Given Imaging Ltd.
Central Denmark Region
Information provided by (Responsible Party):
Rene Oestgaard, Regionshospitalet Silkeborg
ClinicalTrials.gov Identifier:
NCT01174186
First received: July 16, 2010
Last updated: November 6, 2014
Last verified: November 2014
  Purpose

Studies with intestinally asymptomatic patients with spondyloarthritis showed that approximately 1/3 had visible ulcers in the colon by scopic examinations and 2/3 had changes detectable by microscopy. Only those patients who improved in arthritis symptoms showed improvement in colonic changes. In these studies only colon and the terminal ileum was examined. Inflammation of the small intestine was not examined. Newer studies have shown an immunological link between Crohns disease and spondyloarthritis but not ulcerative colitis. The investigators wish to examine the small intestine in these patients before and after treatment, since they expect to find ulcers there linking spondyloarthritis to Crohns disease and healing after treatment.


Condition Intervention Phase
Spondyloarthritis
Enterocolitis
Drug: Adalimumab
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Intestinal Inflammation in Ankylosing Spondylitis Assessed by Fecal Calprotectin, Capsular Endoscopy and Colonoscopy and the Effects of Adalimumab on Mucosal Healing

Resource links provided by NLM:


Further study details as provided by Regionshospitalet Silkeborg:

Primary Outcome Measures:
  • Change Lewis Score Index [ Time Frame: 20 weeks ] [ Designated as safety issue: No ]

    Lewis' score describes the amount of inflammation seen optically by capsular endoscopy.

    Gralnek et al. devised and validated the Lewis score index, based on three endoscopic parameters: villous edema, ulcer and stenosis/stricture. Using these parameters, the authors established a score range of 8-4,800 points where: LS < 135 reflects normal mucosal appearances, LS 135-790 mild mucosal inflammatory change and an LS value ≥790 moderate to severe mucosal inflammatory changes.

    The patients had endoscopy performed at baseline and again after 20 weeks. The number of patients improving was compared to number of patients deteriorating


  • Change in Intestinal Inflammation Measured by Faecal Calprotectin [ Time Frame: 52 weeks ] [ Designated as safety issue: No ]

    Feacal calprotectin is a protein and a marker of the degree of inflammation in the intestine, but not the site of inflammation.

    We measured the level calprotectin continuously in each of the patients. Difference was inferred by repeated measurement ANOVA



Secondary Outcome Measures:
  • Spondyloarthritis Consortium of Canada Score [ Time Frame: one year ] [ Designated as safety issue: No ]
    Inflammation on MRI assessed by the Spondyloarthritis Consortium of Canada score and a Danish scoring method

  • Assessment Group in Ankylosing Spondylitis (ASAS) Core Set for Clinical Practice [ Time Frame: one year ] [ Designated as safety issue: No ]
    clinical measurements of inflammation in spondyloarthritis patients as described by the Assessment Group in Ankylosing Spondylitis (ASAS)


Enrollment: 30
Study Start Date: October 2010
Study Completion Date: March 2014
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Spondyloarthritis
Spondylitis patients with active inflammation. Patients are treated with adalimumab
Drug: Adalimumab
Tumor Necrosis Factor (TNF) alpha inhibitor given 40 mg subcutaneously every other week except the first time where 80 mg is given
Other Name: Humira

Detailed Description:

Patients with inflammatory axial spondyloarthritis according to the assessment group in ankylosing spondylitis (ASAS) criteria (8) and active disease assessed by a physician are recruited in the outpatient clinics of the rheumatology departments, provided that the patient under normal circumstances is expected to benefit from TNF-alpha inhibitor treatment and full fill the criteria for treatment. Screening with a view to participating in the study is carried out in accordance with the inclusion and exclusion criteria. Oral and written patient information about the study, the patient's signing of the informed consent form and the signing of the patient's power of attorney in accordance with the study protocol are also a condition for the inclusion. The including physician will ensure that a potential participant is informed about the right to at least 1 hour's reflection time and the right to have a friend/family member present at the information interview.

If the patient meets the basis for the participation in the study the informed consent form and the power of attorney are signed.

The screened patients are not coded but are identified using their Civil Registration Number (CPR) for several reasons. The study is open-label, which removes the need for blinding of patients as well as investigator. Blood samples are booked electronically and printed labels with CPR number are put on the test tubes for both immediate analysis and storage. This guarantees a more fail-safe method for handling of various analyses, since this procedure is similar to the routine procedure. We find this to be the safest system as the method, by which labels with CPR number follow the patient has been thoroughly tested.

Source data will be kept in the Danish Biologics Online Registry (DANBIO registry) for clinical measures, the electronic patient file for lab data and the paper file for imaging data. Data validity and completeness is controlled by external "good clinical practice" monitoring.

Adalimumab will be supplied as a sterile solution without preservatives for subcutaneous injection in 1 ml prefilled syringes containing adalimumab 40 mg/0.8 ml, to be self-injected by the patient every 2 weeks until week 20. After week 20 patients continue adalimumab treatment 40 mg every other week but may change to injections with pens containing the same drug and dosage. The drug is injected under the skin of the abdomen or the thigh. All patients will be instructed by the study personnel in correct sterile subcutaneous injection of the study drug.

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients (18 years and ≤45 years) with axial SpA according to the ASAS criteria
  • Active SpA assessed by physician.
  • Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≥ 4.
  • Faecal calprotectin ≥ 100mg/kg.
  • Negative pregnancy test (serum-HCG) for women of childbearing age before the start of the study. (Women not of childbearing age are defined as postmenopausal for at least 1 year or surgically sterilised (bilateral tubal ligation, bilateral oophorectomy or hysterectomy)). Women of childbearing age included in the study will be required to use contraception during the entire study period (i.e. one of the following: contraceptive pills, intrauterine device, depot injection of gestagen, subdermal implant, hormonal vaginal ring or transdermal patch). In addition, contraception must be used following any discontinuation of the study drug for a period of 150 days.
  • Ability and willingness to self-administer the subcutaneous injections or have a person available to administer the injections.
  • Ability and willingness to give written informed consent and meet the requirements of the study protocol.

Exclusion Criteria:

  • Diagnosed inflammatory bowel disease or high risk of intestinal stricture (previous abdominal stricture, radiation of abdomen, major abdominal surgery).
  • Non steroid anti inflammatory Drugs (NSAID) ingestion less than 4 weeks before inclusion.
  • Psoriasis
  • Persons with latent Tuberculosis (TB)(positive Mantoux skin test (>10 mm), positive cultivation for mycobacteria in tissue samples and/or chest X-ray indicating TB) or other risk factors for activation of untreated latent TB.
  • Current or recurrent infections or serious infections requiring hospitalisation or treatment with intravenous antibiotics within the last 30 days or oral antibiotics within the last 14 days before inclusion.
  • Positive serology for Hepatitis B or C indicating active infection.
  • Medical history of positive HIV status (in case of suspicion control of HIV test).
  • Medical history of histoplasmosis or listeriosis.
  • Previous cancer or lymphoid proliferative disease except completely well-treated cutaneous squamous cell carcinoma, basal cell carcinoma or cervical dysplasia.
  • Previous diagnosis or signs of demyelinising diseases of the central nervous system (e.g. optic neuritis, disturbance of vision, disturbed gait/ataxia, facial paresis, apraxia).
  • Severe renal insufficiency (creatinine clearance < 35 ml/min - normogram).Affected hepatic function: Liver enzymes > 3 x above the normal limit.
  • Clinically significant drug or alcohol abuse in the last year or daily current alcohol consumption.
  • Diabetes, unstable ischemic heart disease, heart failure (NYHA III-IV), recent apoplexia cerebri (within 3 months), chronic leg ulcer and any other condition (e.g. indwelling catheter) which at the discretion of the investigator means that participation in the protocol would entail a risk for the person in question.
  • Anticoagulant treatment.
  • Pregnancy or breast-feeding.
  • Other clinically significant inflammatory rheumatologic diseases that cannot be related to spondyloarthritis
  • Current parvovirus B 19 infection.
  • Glucocorticosteroid treatment within the last 4 weeks (except nasal and inhalation steroids).
  • Contraindication to study drug.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01174186

Locations
Denmark
Department of Rheumatology U, Aarhus Hospital
Aarhus, Denmark, 8000
Regional Hospital of Horsens, Department of Medicine
Horsens, Denmark, 8700
Regional Hospital of Randers, Department of Medicine
Randers, Denmark
Regional Hospital of Silkeborg
Silkeborg, Denmark, 8600
Sponsors and Collaborators
Regionshospitalet Silkeborg
Abbott
Given Imaging Ltd.
Central Denmark Region
Investigators
Study Chair: Henning Glerup, M.D. Regional Hospital Silkeborg, medical department
Study Director: René D Oestgaard, M.D. Regional Hospital Silkeborg, medical department
Principal Investigator: Bent Deleuran, M.D. Department of Medical Microbiology and Immunology Aarhus University
  More Information

No publications provided

Responsible Party: Rene Oestgaard, René Østgård, MD, Regional Hospital Denmark, medical department, Regionshospitalet Silkeborg
ClinicalTrials.gov Identifier: NCT01174186     History of Changes
Other Study ID Numbers: 4682724
Study First Received: July 16, 2010
Results First Received: April 12, 2014
Last Updated: November 6, 2014
Health Authority: Denmark: Danish Dataprotection Agency
Denmark: Danish Medicines Agency
Denmark: The Regional Committee on Biomedical Research Ethics

Additional relevant MeSH terms:
Enterocolitis
Inflammation
Spondylarthritis
Spondylitis
Spondylitis, Ankylosing
Ankylosis
Arthritis
Bone Diseases
Bone Diseases, Infectious
Digestive System Diseases
Gastroenteritis
Gastrointestinal Diseases
Infection
Intestinal Diseases
Joint Diseases
Musculoskeletal Diseases
Pathologic Processes
Spinal Diseases
Spondylarthropathies
Adalimumab
Anti-Inflammatory Agents
Antirheumatic Agents
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on November 20, 2014